Algorae Pharmaceuticals Ltd (asx:1AI) Share Price

Company Profile

Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUS
T: +61 422180317
https://www.algoraepharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
48

Recommended

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.

William Kerwin, CFA | 12 January 2026

The shares are overvalued as investors are overly excited about defence and gold exposure.

Esther Holloway | 12 January 2026

Our view on the potential for additional offers.

Esther Holloway | 11 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,138.50	11.40	0.12%
CAC 40	8,312.88	45.88	-0.55%
DAX 40	25,374.89	30.45	-0.12%
Dow JONES (US)	49,590.20	86.13	0.17%
FTSE 100	10,135.64	5.06	-0.05%
HKSE	26,848.47	239.99	0.90%
NASDAQ	23,733.90	62.56	0.26%
Nikkei 225	53,549.16	1,609.27	3.10%
NZX 50 Index	13,656.05	27.24	-0.20%
S&P 500	6,977.27	10.99	0.16%
S&P/ASX 200	8,808.50	17.20	0.20%
SSE Composite Index	4,138.76	26.53	-0.64%